It has been about a month since the last earnings report for CRISPR Therapeutics AG (CRSP). Shares have added about 3.3% in that time frame, outperforming the S&P 500. Will the recent positive trend ...

2025 was a great year for mining stocks. However, 2026 is setting up to be a bounce back year for these three Canadian growth ...

CRISPR Therapeutics recently drew attention as updates highlighted progress in its gene-editing pipeline, including early-stage studies of CTX310, an in vivo therapy designed to lower LDL cholesterol ...

Given these factors, my favorite index ETF to outperform in 2026 is the Vanguard Mega Cap Growth ETF as it's one of the most ...

Desjardins analyst Brent Sadler published his year-ahead report for domestic power and utilities stocks, ...

Cathie Wood’s ARK Invest executed a busy week of portfolio adjustments across its ETFs, with several high-conviction ...

Detailed price information for Crispr Therapeutics Ag (CRSP-Q) from The Globe and Mail including charting and trades.

FNDA offers diversified small-cap exposure, attractive valuation versus indices, and lags VUG’s tech-heavy performance. Learn ...

Equity Insider News Commentary ? Traditional pharmaceutical strategies are giving ground as breakthrough approvals for gene therapies and mRNA platforms target previously untreatable rare diseases ...

The board of directors of Morningstar, Inc. , a leading provider of independent investment insights, today declared a quarterly dividend of 50 cents per share, an increase of approximately 10 percent.